公开(公告)号：US20240197900A1

公开(公告)日：2024-06-20

申请号：US18278302

申请日：2022-02-22

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

发明人： Wei HUANG ,  Feng TANG ,  Wei SHI ,  Shang JIAO ,  Siqi WANG

IPC分类号： A61K47/68 ,  A61P35/00 ,  C12N9/04 ,  C12N9/24 ,  C12P19/12

CPC分类号： A61K47/68031 ,  A61K47/68033 ,  A61K47/6883 ,  A61K47/6889 ,  A61P35/00 ,  C12N9/0006 ,  C12N9/2402 ,  C12P19/12 ,  C12Y101/03009 ,  C12Y302/01169

摘要： The present application relates to a disaccharide linker, a disaccharide-small molecule drug conjugate and a sugar chain fixed-point antibody-drug conjugate, a preparation method and the use thereof. The structure of the disaccharide linker is as shown in the following formula I. The present invention provides a new-type fixed-point and quantitative antibody-drug conjugate form, and the stability and cytotoxicity of the antibody-drug conjugate are improved.

公开(公告)号：US20240165229A1

公开(公告)日：2024-05-23

申请号：US18570007

申请日：2022-06-28

申请人： SEAGEN INC.

发明人： Daniel Diolaiti ,  Shyra Gardai

IPC分类号： A61K39/395 ,  A61K31/496 ,  A61K31/635 ,  A61K31/706 ,  A61K47/68 ,  A61P35/02 ,  C07K16/28

CPC分类号： A61K39/3955 ,  A61K31/496 ,  A61K31/635 ,  A61K31/706 ,  A61K47/68031 ,  A61K47/6849 ,  A61P35/02 ,  C07K16/2803 ,  C07K16/2875

摘要： The invention provides methods of treating cancer, such as myeloid malignancies including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), with a nonfucosylated anti-CD70 antibody in combination with a CD47 antagonist.

公开(公告)号：US20240123080A1

公开(公告)日：2024-04-18

申请号：US18448863

申请日：2023-08-11

申请人： Seagen Inc.

发明人： Philip MOQUIST ,  Svetlana DORONINA ,  Nicole DUNCAN ,  Gabriele BLAHNIK-FAGAN ,  Sharsti SANDALL

IPC分类号： A61K47/68 ,  A61K47/54 ,  A61P35/00 ,  C07K5/103

CPC分类号： A61K47/68031 ,  A61K47/543 ,  A61K47/545 ,  A61K47/549 ,  A61K47/6851 ,  A61K47/6889 ,  A61P35/00 ,  C07K5/101

摘要： Hydrophilic auristatin compounds are described, including Drug-Linker compounds, Ligand-Drug Conjugate compounds, methods of use, and preparations thereof.

公开(公告)号：US20240058464A1

公开(公告)日：2024-02-22

申请号：US18260657

申请日：2022-01-06

申请人： Fortis Therapeutics, Inc. ,  The Regents of the University of California

发明人： Bin LIU ,  Andrew DORR ,  Jay LICHTER ,  Marc NASOFF ,  Leonard POST

IPC分类号： A61K47/68 ,  A61K31/4196 ,  A61K31/675 ,  A61K31/7068 ,  A61K31/282 ,  A61K31/58 ,  A61K39/395 ,  A61K31/704 ,  A61K31/44 ,  A61K31/337 ,  A61K33/243 ,  A61P35/00

CPC分类号： A61K47/6849 ,  A61K47/68031 ,  A61K47/6889 ,  A61K31/4196 ,  A61K31/675 ,  A61K31/7068 ,  A61K31/282 ,  A61K31/58 ,  A61K39/3955 ,  A61K31/704 ,  A61K31/44 ,  A61K31/337 ,  A61K33/243 ,  A61P35/00

摘要： Disclosed herein are methods of treating cancer. Some such methods include administration of a first anti-cancer agent that increases CD46 expression on the surface of a cancer cell. Some embodiments include administration of a second anti-cancer agent that binds CD46. The second anti-cancer agent may include an immunoconjugate comprising a CD46 binding domain and effector agent.

公开(公告)号：US20240002527A1

公开(公告)日：2024-01-04

申请号：US18253703

申请日：2021-11-19

申请人： BLISS BIOPHARMACEUTICAL (HANGZHOU) CO., LTD.

发明人： Bing XIA ,  Cui FENG ,  Lixia GU ,  Chen LI ,  Yuhong ZHOU ,  Ziping WEI

IPC分类号： C07K16/28 ,  A61K47/68 ,  A61P35/00

CPC分类号： C07K16/2896 ,  A61K47/6849 ,  A61K47/6889 ,  A61P35/00 ,  A61K47/68031 ,  C07K2317/522 ,  C07K2317/53 ,  A61K2039/505

摘要： Isolated anti-human CD73 antibody includes two heavy chains each including a hinge region comprising an amino acid sequence of that allow site-specific conjugation of cytotoxic drugs. Each heavy chain can include a human CH1 domain located upstream of and connected to the hinge region. The CH1 domain comprising a cysteine at the position of 142 according to the IMGT numbering scheme. ADCs containing the antibody conjugated with a cytotoxic drug are also provided. Pharmaceutical compositions including the antibody or the ADCs, and methods of treating cancer using the pharmaceutical compositions are also provided.

公开(公告)号：US20230364254A1

公开(公告)日：2023-11-16

申请号：US18030225

申请日：2021-10-08

申请人： AGENSYS, INC. ,  SEAGEN INC.

发明人： Elaina Marie GARTNER ,  Eric John CHOWN ,  Tina KIM-HAFKEN ,  Dana Ann KENNEDY

IPC分类号： A61K47/68 ,  A61P35/00 ,  G01N33/50

CPC分类号： A61K47/68031 ,  A61K47/6843 ,  A61P35/00 ,  G01N33/5091 ,  G01N2800/7028 ,  G01N2800/52

摘要： Provided herein are methods for treating cancers with antibody drug conjugates (ADC) that bind to 191P4DI2 protein (Nectin-4).

公开(公告)号：US11807685B2

公开(公告)日：2023-11-07

申请号：US17817448

申请日：2022-08-04

申请人： THE UAB RESEARCH FOUNDATION

发明人： Xiaoguang Margaret Liu

IPC分类号： C12P21/08 ,  A61K39/395 ,  A61K47/68 ,  C07K16/28 ,  C07K16/30 ,  A61P35/00 ,  A61K39/00

CPC分类号： C07K16/2803 ,  A61K47/6803 ,  A61K47/6849 ,  A61P35/00 ,  A61K47/6809 ,  A61K47/68031 ,  A61K47/68033 ,  A61K47/6851 ,  A61K47/6877 ,  A61K2039/505 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92

摘要： Disclosed is an antibody that selectively binds CD47 on tumor cells. Also disclosed is a method for treating cancer in a subject, comprising administering to the subject an effective amount of the antibody disclosed.

公开(公告)号：US20230338569A1

公开(公告)日：2023-10-26

申请号：US17930924

申请日：2022-09-09

申请人： Mersana Therapeutics, Inc.

发明人： Robert A. BURGER

IPC分类号： A61K47/68 ,  C07K16/30

CPC分类号： A61K47/6869 ,  C07K16/3069 ,  A61K47/68031

摘要： Disclosed herein are dosing regimens for a NaPi2b-targeted antibody-drug conjugates for treating recurrent, platinum-sensitive ovarian cancer.

公开(公告)号：US20230331824A1

公开(公告)日：2023-10-19

申请号：US18042448

申请日：2021-08-20

申请人： The Rockefeller University ,  New York University ,  Seattle Children's Hospital d/b/a Seattle Children's Research Institute

发明人： Brian T. Chait ,  Michael P. Rout ,  John Aitchison ,  Fred David Mast ,  Jean Paul Olivier ,  David Fenyo

IPC分类号： C07K16/10 ,  A61K47/68 ,  A61K51/10 ,  C07K14/725 ,  A61K39/00 ,  A61P31/14 ,  C07K16/28 ,  C07K16/18

CPC分类号： C07K16/1003 ,  A61K47/6829 ,  A61K47/6827 ,  A61K47/6825 ,  A61K47/6821 ,  A61K47/6819 ,  A61K47/68031 ,  A61K47/68033 ,  A61K47/6809 ,  A61K47/6805 ,  A61K51/1006 ,  C07K14/7051 ,  A61K39/4631 ,  A61K39/4611 ,  A61K39/464838 ,  A61K39/4633 ,  A61P31/14 ,  C07K16/2809 ,  C07K16/2818 ,  C07K16/2815 ,  C07K16/18 ,  C07K2317/569 ,  C07K2317/52 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2317/31 ,  C07K2319/33 ,  C07K2319/03 ,  C07K2317/76

摘要： Single-domain antibodies that bind the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) spike protein are disclosed. The single-domain antibodies include binding domains that bind epitopes of the Spike ectodomain inside and outside the receptor binding domain. The single-domain antibodies can be used for multiple purposes including in the research, diagnosis, and prophylactic or therapeutic treatment of COVID-19.

公开(公告)号：US20240350835A1

公开(公告)日：2024-10-24

申请号：US18761130

申请日：2024-07-01

申请人： Ambrx, Inc.

发明人： Shivarupam BHOWMIK ,  Jianing WANG ,  Jinming XIA ,  William BRADY ,  Feng TIAN

IPC分类号： A61P35/00 ,  A61K45/06 ,  A61K47/68 ,  C07K16/30

CPC分类号： A61P35/00 ,  A61K47/68031 ,  C07K16/3069 ,  A61K45/06

摘要： The invention relates to prostate specific membrane antigen antibodies (anti-PSMA) and anti-PSMA antibody drug conjugates. The invention also relates to methods and compositions for using anti-PSMA antibody drug conjugates in inhibiting, preventing or treating PSMA related diseases or cancers.